Lynda was diagnosed with stage III invasive lobular breast cancer in 2021. Her treatment included a single left-side mastectomy, followed by chemotherapy, radiation, and immunotherapy. She continues to take hormone therapy, which she expects to continue for at least 10 years.
After completing about two years of treatment, Lynda’s medical oncologist, Dr. Jason Mouabbi, from MD Anderson Cancer Center, recommended that she begin circulating tumor DNA, or ctDNA, testing as part of her follow-up surveillance. The test is now performed every six months, and Lynda’s care team has explained what they would do if a result were to change — including how her prior treatment would guide next steps.
Lobular breast cancer and other breast cancers can return after initial treatment, even years later. In the video, Dr. Mouabbi explains why ctDNA testing is an emerging tool for monitoring for possible recurrence — and why results are always interpreted alongside a person’s cancer type, stage, pathology, treatment history, imaging, and the full clinical picture.
- Lynda’s experience receiving a stage III invasive lobular breast cancer diagnosis
- Her treatment path: mastectomy, chemotherapy, radiation, immunotherapy, and ongoing hormone therapy
- Why breast cancer can return after treatment, and why follow-up surveillance matters
- What ctDNA is and how a blood test can detect DNA shed by cancer cells
- How ctDNA testing may offer a “lead time,” potentially signaling recurrence risk before a scan can
- What a positive or negative result means — including the value of repeated testing over time
- Why ctDNA results should be interpreted with pathology, cancer stage, imaging, treatment history, and other clinical information
- Lynda’s advice: don’t be afraid of the test, and advocate for information that can help you and your care team plan ahead
Circulating tumor DNA, or ctDNA, is DNA from cancer cells that can sometimes be found in the bloodstream. As cells break down, they can release DNA into the blood. A ctDNA test looks for DNA associated with a person’s tumor.
Dr. Mouabbi explains that historically, after surgery and adjuvant treatment for early-stage breast cancer, follow-up relied on a patient reporting symptoms — which would then prompt imaging. By the time a recurrence is visible on a scan, the disease is often already metastatic. ctDNA testing may provide a lead time, potentially detecting a signal of recurrence months to years before it would appear on imaging, which is why some care teams are incorporating it into surveillance.
A ctDNA test alone does not diagnose a recurrence or determine treatment. But as Dr. Mouabbi describes, studies show the test has prognostic utility — it can help predict whether breast cancer is likely to come back. A positive result that remains positive over time strongly suggests the cancer will return at some point, although the timing of when it might be seen on a scan — a month, six months, a year, or longer — is not known. A single negative result is reassuring but not a guarantee; Dr. Mouabbi notes a negative predictive value of about 94%, meaning there remains a small chance of a false negative. Studies suggest that repeated negative results over time — “serial negativity” — increase that confidence, which is one reason continued testing can have value.
There is also early evidence that ctDNA can help predict response to therapy: data suggest that clearing ctDNA — going from positive to negative — is associated with improved outcomes, though more research is underway to confirm how this information should guide treatment decisions.
Follow-up care after treatment for stage III breast cancer is designed to monitor for possible recurrence and to address each person’s individual risk. The timing and intensity of surveillance may differ based on the cancer’s type, stage, and biology, the treatment received, and other personal factors.
For Lynda, ctDNA testing began about two years after treatment and is currently performed every six months. This schedule is specific to her care plan and should not be considered a standard schedule for all people with breast cancer.
A detectable or rising ctDNA result can be a signal for the care team to look more closely, even before imaging identifies anything. Conversely, an undetectable result can be reassuring, but it does not eliminate the need for recommended appointments, imaging, laboratory tests, and other standard follow-up care.
Questions to ask your care team
If you have been treated for early-stage breast cancer or are planning follow-up, you may want to ask:
- What is my individual risk that breast cancer could return after treatment?
- What follow-up tests, scans, and appointments are recommended for me?
- Is ctDNA testing appropriate for my type and stage of breast cancer?
- What question would ctDNA testing help answer in my situation?
- How would a detectable or rising ctDNA result affect my surveillance plan?
- What would an undetectable result mean, and what follow-up would I still need?
- How often might testing be performed, and could that schedule change over time?
- Is ctDNA testing covered by my insurance, and are financial-assistance options available?
- Are there clinical trials evaluating ctDNA-guided monitoring or treatment in breast cancer that may be appropriate for me?
Lynda’s experience underscores the value of an individualized follow-up plan after breast cancer treatment. As Dr. Mouabbi notes, ctDNA testing is widely available — patients can ask their oncologist about it, learn what their team knows about it, and make an informed, shared decision about whether it is appropriate for them. Talk with your oncology team about your recurrence risk, your recommended surveillance schedule, and whether ctDNA testing may provide useful additional information in your situation.
Patient information disclaimer
Lynda’s experience is personal and may not represent the experience of every person with breast cancer. ctDNA testing is not appropriate for every patient and does not replace mammography, imaging, laboratory testing, physical examination, clinical follow-up, or individualized guidance from an oncology care team. Patients should discuss their diagnosis, treatment history, recurrence risk, and follow-up options with their doctor.
This educational resource was made possible by Natera, OmniOncology, and The Personalized Medicine Foundation.
More in this series
- Ken’s Story: Understanding ctDNA After Colorectal Cancer Surgery
- Ken’s Story: Using ctDNA to Help Navigate Colorectal Cancer Follow-Up
- Mary Jo’s Story: ctDNA Monitoring, MSI-High Colorectal Cancer, and Immunotherapy
- Shawn’s Story: ctDNA Monitoring After Treatment for Muscle-Invasive Bladder Cancer
- Linda’s Story: ctDNA in Stage IV Breast Cancer- Is My Treatment Working?





